Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Sci Adv ; 6(12): eaax7945, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32219156

RESUMEN

Because of its key role in cancer development and progression, STAT3 has become an attractive target for developing new cancer therapeutics. While several STAT3 inhibitors have progressed to advanced stages of development, their underlying biology and mechanisms of action are often more complex than would be expected from specific binding to STAT3. Here, we have identified and optimized a series of compounds that block STAT3-dependent luciferase expression with nanomolar potency. Unexpectedly, our lead compounds did not bind to cellular STAT3 but to another prominent anticancer drug target, TrxR1. We further identified that TrxR1 inhibition induced Prx2 and STAT3 oxidation, which subsequently blocked STAT3-dependent transcription. Moreover, previously identified inhibitors of STAT3 were also found to inhibit TrxR1, and likewise, established TrxR1 inhibitors block STAT3-dependent transcriptional activity. These results provide new insights into the complexities of STAT3 redox regulation while highlighting a novel mechanism to block aberrant STAT3 signaling in cancer cells.


Asunto(s)
Antineoplásicos/farmacología , Inhibidores Enzimáticos/farmacología , Factor de Transcripción STAT3/antagonistas & inhibidores , Tiorredoxina Reductasa 1/antagonistas & inhibidores , Antineoplásicos/química , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Genes Reporteros , Humanos , Factor 2 Relacionado con NF-E2/agonistas , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Factor de Transcripción STAT3/metabolismo , Activación Transcripcional/efectos de los fármacos
2.
Sci Adv ; 6(1): eaax8358, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31911946

RESUMEN

Irreversible oxidation of Cys residues to sulfinic/sulfonic forms typically impairs protein function. We found that persulfidation (CysSSH) protects Cys from irreversible oxidative loss of function by the formation of CysSSO1-3H derivatives that can subsequently be reduced back to native thiols. Reductive reactivation of oxidized persulfides by the thioredoxin system was demonstrated in albumin, Prx2, and PTP1B. In cells, this mechanism protects and regulates key proteins of signaling pathways, including Prx2, PTEN, PTP1B, HSP90, and KEAP1. Using quantitative mass spectrometry, we show that (i) CysSSH and CysSSO3H species are abundant in mouse liver and enzymatically regulated by the glutathione and thioredoxin systems and (ii) deletion of the thioredoxin-related protein TRP14 in mice altered CysSSH levels on a subset of proteins, predicting a role for TRP14 in persulfide signaling. Furthermore, selenium supplementation, polysulfide treatment, or knockdown of TRP14 mediated cellular responses to EGF, suggesting a role for TrxR1/TRP14-regulated oxidative persulfidation in growth factor responsiveness.


Asunto(s)
Cisteína/genética , Oxidación-Reducción/efectos de los fármacos , Tiorredoxina Reductasa 1/genética , Tiorredoxinas/genética , Animales , Cisteína/química , Factor de Crecimiento Epidérmico/genética , Proteínas HSP90 de Choque Térmico/genética , Proteínas de Homeodominio/química , Proteínas de Homeodominio/genética , Humanos , Proteína 1 Asociada A ECH Tipo Kelch/genética , Ratones , Fosfohidrolasa PTEN/genética , Proteína Tirosina Fosfatasa no Receptora Tipo 1/genética , Selenio/farmacología , Transducción de Señal/efectos de los fármacos , Sulfuros/metabolismo , Sulfuros/farmacología , Tiorredoxina Reductasa 1/química , Tiorredoxinas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA